

TUMOR ANALYSIS REQUISITION

PATIENT INFORMATION (COMPLETE ONE FORM FOR EACH PERSON TESTED)

Patient Last Name		Patient First Name		MI	Date of Birth (MM / DD / YYYY)
Address			City	State	ZIP* (required for ClariFind™ testing for clinical trial matching)
Phone	Accession #	Hospital / Medical Record #		Patient discharged from the hospital/facility: <input type="radio"/> Yes <input type="radio"/> No	
Biological Sex: <input type="radio"/> Female <input type="radio"/> Male <input type="radio"/> Unknown Gender identity (if different from left): _____					

* If patient ZIP code is not provided for ClariFind testing, Baylor Genetics will defer to the ZIP code of the forwarding institution.

REPORTING RECIPIENTS

Ordering Physician	Institution Name	
Email (Required for International Clients)	Phone	Fax

ADDITIONAL RECIPIENTS

Name	Email	Fax
Name	Email	Fax

PAYMENT (FILL OUT ONE OF THE OPTIONS BELOW)

SELF PAYMENT

Pay With Sample Bill To Patient

INSTITUTIONAL BILLING

Institution Name	Institution Code	Institution Contact Name	Institution Phone	Institution Contact Email
------------------	------------------	--------------------------	-------------------	---------------------------

INSURANCE

Do Not Perform Test Until Patient is Aware of Out-Of-Pocket Costs (excludes prenatal testing)

REQUIRED ITEMS 1. Copy of the Front/Back of Insurance Card(s) 2. ICD10 Diagnosis Code(s) 3. Name of Ordering Physician 4. Insured Signature of Authorization

Name of Insured	Inured Date of Birth (MM / DD / YYYY)	Name of Insured	Inured Date of Birth (MM / DD / YYYY)		
Patient's Relationship to Insured	Phone of Insured	Patient's Relationship to Insured	Phone of Insured		
Address of Insured		Address of Insured			
City	State	ZIP	City	State	ZIP
Primary Insurance Co. Name	Primary Insurance Co. Phone	Secondary Insurance Co. Name	Secondary Insurance Co. Phone		
Primary Member Policy #	Primary Member Group #	Secondary Member Policy #	Secondary Member Group #		

By signing below, I hereby authorize Baylor Genetics to provide my insurance carrier any information necessary, including test results, for processing my insurance claim. I understand that I am responsible for any co-pay, co-insurance, and unmet deductible that the insurance policy dictates, as well as any amounts not paid by my insurance carrier for reasons including, but not limited to, non-covered and non-authorized services. I understand that I am responsible for sending Baylor Genetics any and all payments that I receive directly from my insurance company in payment for this test. Please note that Medicare does not cover routine screening tests.

Patient's Printed Name	Patient's Signature	Date (MM / DD / YYYY)
------------------------	---------------------	-----------------------

STATEMENT OF MEDICAL NECESSITY (REQUIRED)

This test is medically necessary for the risk assessment, diagnosis, or detection of a disease, illness, impairment, symptom, syndrome, or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the Ordering Physician is authorized by law to order the test(s) requested herein. I confirm that I have provided genetic testing information to the patient and they have consented to genetic testing.

Physician's Printed Name	Physician's Signature	Date (MM / DD / YYYY)
--------------------------	-----------------------	-----------------------

TUMOR ANALYSIS REQUISITION

Patient Last Name _____
Patient First Name _____
MI _____ / _____ / _____
Date of Birth (MM / DD / YYYY) _____
Biological Sex _____
ZIP (required for ClariFind)

ETHNICITY

- African American
- Ashkenazi Jewish
- East Asian (China, Japan, Korea)
- Finnish
- French Canadian
- Hispanic American
- Mennonite
- Middle Eastern (Saudi Arabia, Qatar, Iraq, Turkey)
- Native American
- Northern European Caucasian (Scandinavian, UK, Germany)
- Pacific Islander (Philippines, Micronesia, Malaysia, Indonesia)
- South Asian (India, Pakistan)
- Southeast Asian (Vietnam, Cambodia, Thailand)
- Southern European Caucasian (Spain, Italy, Greece)
- Other (Specify): _____

SAMPLE INFORMATION

Date of Collection (MM / DD / YYYY) _____
Time of Collection

NOTE: Extracted DNA/RNA will only be accepted if the isolation of nucleic acids for clinical testing occurs in a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/or the CMS.

REQUIRED FOR BREAST CANCER FFPE SAMPLES

Method of Fixation _____
Time to Tissue Fixation _____
Tissue Fixation Time

SAMPLE TYPE (PLEASE REFER TO PAGE 5 FOR SAMPLE REQUIREMENTS)

- Blood in EDTA Tube (Purple-Top) +
- Blood in Sodium Heparin (Green-Top) +
- Bone Marrow in Sodium Heparin (Green-Top) +
- Bone Marrow in EDTA (Purple-Top) +
- FFPE - Slides * #: _____
- FFPE - Tissue Block *
- Fresh Frozen Tissue ±*
- Tissue in Medium ±*
- DNA (Concentration) + ±*: _____
- RNA (Concentration) + ±*: _____
- Other **: _____

+ For hematologic samples, attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory reports may be sent later as soon as available.

* Surgical Pathology report MUST be attached for all tissue samples but may be sent later as soon as it becomes available.

** Please call for consultation before ordering test.

* Please send a corresponding representative H+E slide, if available.

Gender of Bone Marrow Transplant Donor Female Male
(select one):

INDICATION FOR TESTING (REQUIRED)

Indication(s)

ICD10 Diagnosis Code(s)

RETURN OF FFPE SPECIMENS

Check if block and/or H&E stained slide should be returned. Fill out the return address information below, or affix preprinted label.

This section will be used as the return address label.

Institution _____
ATTN

Address

City _____
State _____
ZIP _____

SPECIMEN RETRIEVAL

I want Baylor Genetics to request the specimen. (Complete information below)

Location of Specimen

Contact Name

Phone # _____
Fax # _____

TUMOR ANALYSIS REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Biological Sex _____ ZIP (required for ClariFind) _____

TUMOR PROFILING BY NEXT-GENERATION SEQUENCING

BE = Blood in EDTA (purple-top) **BME** = Bone Marrow in EDTA (purple-top) **TM** = Tissue in Medium **SA** = Saliva
FFPE = Slides/Block **T** = Fresh Frozen Tissue **DNA** = DNA, Extracted

TEST CODE	TEST NAME	SAMPLE TYPE	SPECIAL NOTES
<input type="checkbox"/> 20010	ClariFind™ Comprehensive DNA Panel	BE, BME, FFPE, T, TM, DNA	DNA coverage for all coding (exonic) regions of 277 key cancer genes for both solid tumors and hematologic malignancies. For further details, please visit baylorgenetics.com/ClariFind.
<input type="checkbox"/> 8085	ClariFind™ FISH Panel for Solid Tumors (ALK rearrangement, ERBB2 (HER2/neu), MET amplification, MYC translocation, RET rearrangement, ROS1 rearrangement)	FFPE	FISH testing for gene rearrangements and amplifications pertinent for several types of solid tumors. For additional FISH testing options, please see below and next page. For FFPE slides, please send additional 20 slides.

ADDITIONAL TESTING RECOMMENDATIONS

TEST CODE	TEST NAME	SAMPLE TYPE	DISEASE	SPECIAL NOTES
<input type="checkbox"/> 9505	180K CGH/SNP Array	BE, BME, FFPE, T		180K CGH/SNP Array should be considered for genomic copy number analysis. For FFPE slides, please send additional 20 slides.
<input type="checkbox"/> 9150	Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR	FFPE		Please submit BOTH a source of tumor tissue (FFPE block/slides) AND a source of normal tissue (FFPE block/slides). Testing will be sent to ARUP Laboratories for analysis and reporting.
<input type="checkbox"/> 8976	PD-L1 28-8 pharmDx by Immunohistochemistry with Interpretation, nivolumab (OPDIVO)	FFPE	Solid Tumors	For patients with non-squamous non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, or head and neck squamous cell carcinoma (HNSCC). For FFPE slides, please send additional 5 slides. Test will be sent to ARUP Laboratories for analysis and reporting.
<input type="checkbox"/> 8977	PD-L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA)	FFPE		Use for gastric/GEJ, urothelial, and cervical specimens only. For FFPE slides, please send additional 5 slides. Test will be sent to ARUP Laboratories for analysis and reporting.
<input type="checkbox"/> 8787	Non-Small Cell Lung Carcinoma FISH Panel (ALK rearrangement, MET amplification, RET rearrangement, ROS1 rearrangement)	FFPE	Non-Small Cell Lung Cancer	FISH testing for ALK, MET, RET, and ROS1 should be considered if not previously performed. For FFPE slides, please send additional 3-5 slides per probe.
<input type="checkbox"/> 8975	PD-L1 22C3 IHC for NSCLC by Immunohistochemistry with Interpretation, pembrolizumab (KEYTRUDA)	FFPE		Use for non-small cell lung cancer (NSCLC) specimens only. For FFPE slides, please send additional 5 slides. Test will be sent to ARUP Laboratories for analysis and reporting.
<input type="checkbox"/> 8025	ERBB2 (HER2/neu)	FFPE	Breast Cancer or Gastric Cancer	FISH testing for HER2 should be considered as clinically appropriate and if HER2 testing (immunohistochemistry and/or FISH) not previously performed. For FFPE slides, please send additional 3-5 slides.
<input type="checkbox"/> 8300	Classical Chromosome Analysis - Hematologic Cancer	BH, BMH		Classical chromosomal analysis and appropriate FISH studies should be considered if not previously performed (please also see next page).
<input type="checkbox"/> 9045	FLT3 Mutation Detection by PCR	BE, BME	Hematologic Malignancies	FLT3 mutation testing by PCR should be considered for acute myeloid leukemia. FLT3 testing will be sent to LabPMM for analysis and reporting.
<input type="checkbox"/> 9515	CytoScan HD SNP Array	BE, BME, T		CytoScan HD SNP Array should be considered for genomic copy number analysis.
<input type="checkbox"/> 8789	Aggressive/High-Grade B-Cell Lymphoma FISH Panel (MYC translocation, BCL2 rearrangement, BCL6 rearrangement)	FFPE	Aggressive/High-Grade B-Cell Lymphoma	FISH testing for MYC, BCL2, and BCL6 should be considered if not previously performed. For FFPE slides, please send additional 3-5 slides per probe.

TEST CODE	GENE (REQUIRED)	VARIANT (REQUIRED)	SAMPLE TYPE	DISEASE	SPECIAL NOTES
<input type="checkbox"/> 1566	Custom Sequence Analysis - Variant 1	_____			These tests can only be requested on a germline sample for patients with previous variant(s) detected by ClariFind. Complete one test code request for EACH variant. If more than 3 variants are desired, please contact a Baylor Genetics representative at 1.800.411.4363. Please provide the lab number listed on the top of the ClariFind report here:
<input type="checkbox"/> 1567	Custom Sequence Analysis - Variant 2	_____	BE, DNA, SA, TM	Germline	
<input type="checkbox"/> 1568	Custom Sequence Analysis - Variant 3	_____			

TUMOR ANALYSIS REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Biological Sex _____ ZIP (required for ClariFind) _____

CANCER MOLECULAR ANALYSIS

BE = Blood in EDTA (purple-top) **BME** = Bone Marrow in EDTA (purple-top)
FFPE = Slides/Block **T** = Fresh Frozen Tissue

NOTE: For Molecular Tests, Bone Marrow and Blood are REQUIRED to be collected in EDTA (PURPLE-TOP) TUBES

CHROMOSOMAL MICROARRAY

TEST CODE	TEST NAME	SAMPLE TYPE
<input type="checkbox"/> 9515	CytoScan HD SNP Array (for Hematologic Malignancies)	BE, BME, T
<input type="checkbox"/> 9505	180K CGH/SNP Array (for Solid Tumors) ¹	BE, BME, FFPE, T

SINGLE GENE TESTING

All single gene tests will be sent out to ARUP Laboratories for analysis and reporting unless otherwise noted.

TEST CODE	TEST NAME	SAMPLE TYPE
<input type="checkbox"/> 9202	B-Cell Clonality Screening (IgH and IgK) by PCR	BE, BME, FFPE, T
<input type="checkbox"/> 9065	BCR-ABL1, Major (p210), Quantitative	BE, BME
<input type="checkbox"/> 8972	BCR-ABL1, Minor (p190), Quantitative	BE, BME
<input type="checkbox"/> 9070	BCR-ABL1, Qualitative Analysis w/ Reflex to BCR-ABL1 Quantitative	BE, BME
<input type="checkbox"/> 9305	BCR-ABL1 Mutation Analysis for Tyrosine Kinase Inhibitor Resistance by NGS	BE, BME
<input type="checkbox"/> 9003	BRAF V600 Mutation Analysis	BE, BME, FFPE
<input type="checkbox"/> 9016	CALR (Calreticulin) Exon 9 Mutation Analysis by PCR	BE, BME
<input type="checkbox"/> 9086	CEBPA Mutation Detection	BE, BME
<input type="checkbox"/> 9030	EGFR Mutation Detection by Pyrosequencing	FFPE
<input type="checkbox"/> 9045	FLT3 Mutation Detection by PCR ²	BE, BME
<input type="checkbox"/> 9104	Gastrointestinal Stromal Tumor Mutation (KIT, PDGFRA)	FFPE
<input type="checkbox"/> 9060	IGHV Mutation Analysis by Sequencing	BE, BME
<input type="checkbox"/> 9015	JAK2 Exon 12 Mutation Analysis by PCR	BE, BME
<input type="checkbox"/> 9010	JAK2 Gene, V617F Mutation, Qualitative	BE, BME
<input type="checkbox"/> 8970	KIT (D816V) Mutation by PCR	BE, BME
<input type="checkbox"/> 9103	KIT Mutations, Melanoma (including PDGFRA)	FFPE
<input type="checkbox"/> 9105	KIT Mutations in AML by Fragment Analysis and Sequencing	BE, BME
<input type="checkbox"/> 9128	KRAS Mutation Detection	FFPE
<input type="checkbox"/> 8974	MGMT Methylation Detection by PCR	FFPE
<input type="checkbox"/> 9150	Microsatellite Instability (MSI), HNPCC/Lynch Syndrome, by PCR ³	FFPE
<input type="checkbox"/> 9020	MPL Codon 515 Mutation Detection by Pyrosequencing, Quantitative	BE, BME
<input type="checkbox"/> 8973	MYD88 L265P Mutation Detection by PCR, Quantitative	BE, BME, FFPE
<input type="checkbox"/> 9005	NPM1 Mutation Detection by RT-PCR, Quantitative	BE, BME
<input type="checkbox"/> 8971	NRAS Mutation Detection by Pyrosequencing	FFPE
<input type="checkbox"/> 8976	PD-L1 28-8 pharmDx by Immunohistochemistry with Interpretation, nivolumab (OPDIVO)	FFPE
<input type="checkbox"/> 8975	PD-L1 22C3 IHC for NSCLC by Immunohistochemistry with Interpretation, pembrolizumab (KEYTRUDA)	FFPE
<input type="checkbox"/> 8977	PD-L1 22C3 IHC with Combined Positive Score (CPS) Interpretation, pembrolizumab (KEYTRUDA)	FFPE
<input type="checkbox"/> 9080	PML-RARA Translocation, t(15;17) by RT-PCR, Quantitative	BE, BME
<input type="checkbox"/> 9217	T-Cell Clonality Screening by PCR	BE, BME, FFPE, T
<input type="checkbox"/> 9055	TP53 Somatic Mutation, Prognostic	BE, BME, FFPE

REFLEX TESTS

Reflex Request (Please describe below):

¹ For test code 9505: If sending FFPE slides, 20 slides are required for submission.
² For test code 9045: Test will be sent to LabPMM for analysis and reporting.
³ For test code 9150: Please submit BOTH a source of tumor tissue (FFPE block/slides) AND a source of normal tissue (FFPE block/slides).

CYTOGENETIC TESTS

BH = Blood in Sodium Heparin (green-top) **BMH** = Bone Marrow in Sodium Heparin (green-top)
TM = Tissue in Medium **FFPE** = Slides/Block

NOTE: Bone Marrow and Blood are REQUIRED to be collected in SODIUM HEPARIN (GREEN-TOP) TUBES

SINGLE FISH PROBES

TEST CODE	TEST NAME	SAMPLE TYPE
<input type="checkbox"/> 8055	1p/19q Co-deletion	FFPE
<input type="checkbox"/> 8030	ALK Rearrangement	FFPE
<input type="checkbox"/> 8725	AML1/ETO: t(8;21) [AML]	BH, BMH
<input type="checkbox"/> 8785	BCL2 Rearrangement	FFPE
<input type="checkbox"/> 8775	BCL6 Rearrangement	BH, BMH, FFPE
<input type="checkbox"/> 8750	BCR/ABL: t(9;22) [CML/ALL/AML]	BH, BMH
<input type="checkbox"/> 8740	CBFB: inv(16) [AML]	BH, BMH
<input type="checkbox"/> 8730	CHIC2: Deleted 4q [Hypereosinophilic Syndrome]	BH, BMH
<input type="checkbox"/> 8710	Deletion 5: [MDS]	BH, BMH
<input type="checkbox"/> 8715	Deletion 7: [MDS]	BH, BMH
<input type="checkbox"/> 8720	Deletion 20q12: [MDS]	BH, BMH
<input type="checkbox"/> 8065	DXZ1/DYZ3	BH, BMH
<input type="checkbox"/> 8035	EGFR	FFPE
<input type="checkbox"/> 8025	ERBB2 (HER2/neu)	FFPE
<input type="checkbox"/> 8385	Gain Chromosome 8	BH, BMH
<input type="checkbox"/> 8780	IGH Rearrangement	BH, BMH
<input type="checkbox"/> 8765	IGH/BCL2: t(14;18) [Follicular Lymphoma]	BH, BMH, FFPE
<input type="checkbox"/> 8770	IGH/CCND1: t(11;14) [Mantle Cell Lymphoma]	BH, BMH, FFPE
<input type="checkbox"/> 8786	MALT1 Lymphoma	BH, BMH
<input type="checkbox"/> 8095	MET Amplification	FFPE
<input type="checkbox"/> 8745	MLL: 11q23	BH, BMH
<input type="checkbox"/> 8760	MYC translocation	BH, BMH, FFPE
<input type="checkbox"/> 8788	p53	BH, BMH
<input type="checkbox"/> 8735	PML/RARA: t(15;17) [AML]	BH, BMH
<input type="checkbox"/> 8031	RET Rearrangement	FFPE
<input type="checkbox"/> 8781	ROS1 Rearrangement	FFPE
<input type="checkbox"/> 8075	SS18 [Synovial Sarcoma]	FFPE
<input type="checkbox"/> 8080	TCF3/PBX1 [ALL]	BH, BMH
<input type="checkbox"/> 8755	TEL/AML1: t(12;21) [ALL]	BH, BMH
<input type="checkbox"/> 8400	OTHER, Probe Name: _____	

CLASSICAL CHROMOSOME ANALYSIS

TEST CODE	TEST NAME	SAMPLE TYPE
<input type="checkbox"/> 8300	Hematologic Cancer	BH, BMH
<input type="checkbox"/> 8050	Solid Tumor	TM

FISH PANELS

TEST CODE	TEST NAME	SAMPLE TYPE
<input type="checkbox"/> 8789	Aggressive/High-Grade B-Cell Lymphoma (MYC translocation, BCL2 rearrangement, BCL6 rearrangement)	FFPE
<input type="checkbox"/> 8010	ALL (MYB del, CDKN2A del, BCR/ABL, TEL/AML1, MLL rearrangement, IGH rearrangement)	BH, BMH
<input type="checkbox"/> 8000	AML (Trisomy 8, AML/ETO, MLL rearrangement, PML/RARA, CBFB inversion)	BH, BMH
<input type="checkbox"/> 8040	CLL (MYB del, ATM del, Trisomy 12, 13 del, p53 del, IGH rearrangement)	BH, BMH
<input type="checkbox"/> 8005	MDS (5 del, 7 del, Trisomy 8, MLL rearrangement, 20q del)	BH, BMH
<input type="checkbox"/> 8015	Multiple Myeloma (Trisomy 9, RB1 del, IGH rearrangement, Trisomy 15, p53 del)	BH, BMH
<input type="checkbox"/> 8020	NHL (ALK rearrangement, BCL-6 rearrangement, ATM & p53 del, IGH rearrangement)	BH, BMH
<input type="checkbox"/> 8787	Non-Small Cell Lung Carcinoma (ALK rearrangement, MET amplification, RET rearrangement, ROS1 rearrangement)	FFPE



TUMOR ANALYSIS REQUISITION

Patient Last Name _____ Patient First Name _____ MI _____ Date of Birth (MM / DD / YYYY) _____ Biological Sex _____ ZIP (required for ClariFind) _____

SAMPLE SPECIFICATIONS TABLE

FOR CLIENT INFORMATION ONLY. Not required with sample submission.

ABBREVIATION	SAMPLE NAME	RECOMMENDED AMOUNT		SHIPPING INSTRUCTIONS	SPECIAL NOTES
		(2 YRS - ADULT)	(NEWBORN - 2YRS)		
BE	Blood in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
BH	Blood in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
BME	Bone Marrow in EDTA tube (purple-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
BMH	Bone Marrow in Sodium Heparin tube (green-top)	3 - 5 cc	2 -3 cc	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 24-48 hours of collection.	Attach clinical notes and concurrent laboratory reports (such as CBC, flow cytometry, cytogenetics, FISH, molecular testing, and pathology reports). Concurrent laboratory results may be sent later as soon as available.
DNA	DNA, Extracted	At Least 100 ng	At Least 100 ng	Ship at room or refrigerated temperature in an insulated container by overnight courier. May also be shipped frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
FFPE	FFPE - Block	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	Paraffin-embedded, formalin-fixed tissue block containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm ²). Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples.
FFPE	FFPE - Slides	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. If shipping during the summer months please include a cold-pack to avoid extreme temperatures. Do not heat or freeze.	10 - 15 unstained 5µm FFPE slides containing ≥20% tumor nuclei with a minimum tumor surface area of 5mm x 5mm (25mm ²). For smaller specimens, 20 or more unstained 5µm FFPE slides containing ≥20% tumor nuclei should be submitted. Decalcified specimens are not accepted. Surgical pathology report must be attached for all tissue samples. For test codes 9505: 20 slides are required for submission.
RNA	RNA, Extracted	At Least 100 ng	At Least 100 ng	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Minimum concentration of 25ng/uL. Attach clinical notes, concurrent laboratory reports, and/or surgical pathology report, as applicable. Please send a corresponding representative H+E slide, if available.
SA	Saliva	See Special Notes	See Special Notes	Ship at room temperature in an insulated container by overnight courier. Do not heat or freeze.	Collected with Oragene DNA Self-Collection Kit (provided by Baylor Genetics with instructions).
T	Fresh Frozen Tissue	150 mg	150 mg	Ship frozen on minimum of 10 lbs of dry ice in an insulated container by overnight courier.	Fresh tissue snap frozen at ≤-20°C. Store at ≤-20°C. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.
TM	Fresh Tissue in Medium	0.5 - 1 cm ³ or more	0.5 - 1 cm ³ or more	Ship at room or refrigerated temperature in an insulated container by overnight courier. Do not heat or freeze. Specimen should arrive in the laboratory within 48 hours of collection.	Transport tumor tissue in a sterile, screw-top container filled with tissue culture transport medium. If tissue culture transport medium is not available, collect in plain RPMI, Hanks solution, or saline. Surgical pathology report must be attached for all tissue samples. Surgical pathology report may be sent later as soon as it becomes available. Please send a corresponding representative H+E slide, if available.